<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested parenteral antibiotic regimens for mastitis or breast abscess in infants without severe complications,* according to most frequent gram stain findings</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested parenteral antibiotic regimens for mastitis or breast abscess in infants without severe complications,* according to most frequent gram stain findings</h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested parenteral antibiotic regimens for mastitis or breast abscess in infants without severe complications,* according to most frequent gram stain findings</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33.33%"></colgroup> <tbody> <tr> <td class="subtitle1">Parenteral antibiotics</td> <td class="subtitle1">Infants ≤28 days</td> <td class="subtitle1">Infants &gt;28 days</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Gram-positive cocci</td> </tr> <tr> <td class="indent1" colspan="3"><strong>CA-MRSA not a concern (one of the following)</strong></td> </tr> <tr> <td class="indent2">Nafcillin or oxacillin</td> <td> <ul> <li><strong>GA ≤34 weeks:</strong> <ul> <li>Age ≤7 days: 25 mg/kg IV every 12 hours</li> <li>Age &gt;7 days: 25 mg/kg IV every 8 hours</li> </ul> </li> <li><strong>GA &gt;34 weeks:</strong> <ul> <li>Age ≤7 days: 25 mg/kg IV every 8 hours</li> <li>Age &gt;7 days: 25 mg/kg IV every 6 hours</li> </ul> </li> </ul> </td> <td> <ul> <li>100 to 200 mg/kg IV per day in 4 to 6 doses</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong>CA-MRSA a concern (one of the following)</strong></td> </tr> <tr> <td class="indent2">Clindamycin<sup>¶</sup></td> <td> <ul> <li>PMA ≤32 weeks: 5 mg/kg IV every 8 hours</li> <li>PMA 33 to 40 weeks: 7 mg/kg IV every 8 hours</li> <li>PMA &gt;40 weeks: 9 mg/kg IV every 8 hours</li> </ul> </td> <td> <ul> <li>20 to 40 mg/kg IV per day in 3 or 4 doses</li> </ul> </td> </tr> <tr> <td class="indent2">Vancomycin<sup>Δ</sup></td> <td> <ul> <li>Loading dose: 20 mg/kg IV</li> <li>Maintenance dosing according to GA and serum creatinine as indicated below. The interval between the loading dose and the first maintenance dose should be the same as the dosing interval for the maintenance regimen. This dosing regimen was designed with a target trough concentration of 5 to 10 mg/L <sup>[1]</sup>. <ul> <li><strong>GA ≤28 weeks:</strong> <ul> <li>&lt;0.5 mg/dL: 15 mg/kg IV every 12 hours</li> <li>0.5 to 0.7 mg/dL: 20 mg/kg IV every 24 hours</li> <li>0.8 to 1 mg/dL: 15 mg/kg IV every 24 hours</li> <li>1.1. to 1.4 mg/dL: 10 mg/kg IV every 24 hours</li> <li>&gt;1.4 mg/dL: 15 mg/kg IV every 48 hours</li> </ul> </li> <li><strong>GA &gt;28 weeks:</strong> <ul> <li>&lt;0.7 mg/dL: 15 mg/kg IV every 12 hours</li> <li>0.7 to 0.9 mg/dL: 20 mg/kg IV every 24 hours</li> <li>1 to 1.2 mg/dL: 15 mg/kg IV every 24 hours</li> <li>1.3 to 1.6 mg/dL: 10 mg/kg IV every 24 hours</li> <li>&gt;1.6 mg/dL: 15 mg/kg IV every 48 hours</li> </ul> </li> </ul> </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content related to alternative methods of dosing vancomycin for children older than 28 days<sup>◊</sup></li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Gram-negative organisms (one of the following)</td> </tr> <tr> <td class="indent1">Gentamicin<sup>§</sup></td> <td> <ul> <li><strong>GA &lt;30 weeks:</strong> <ul> <li>Age ≤14 days: 5 mg/kg IV every 48 hours</li> <li>Age &gt;14 days: 5 mg/kg IV every 36 hours</li> </ul> </li> <li><strong>GA 30 to 34 weeks:</strong> <ul> <li>Age ≤10 days: 5 mg/kg IV every 36 hours</li> <li>Age &gt;10 days: 5 mg/kg IV every 24 hours</li> </ul> </li> <li><strong>GA ≥35 weeks:</strong> <ul> <li>Age ≤7 days: 4 mg/kg IV every 24 hours</li> <li>Age &gt;7 days: 5 mg/kg IV every 24 hours</li> </ul> </li> </ul> </td> <td> <ul> <li>6 to 7.5 mg/kg IV per day in 3 doses, or</li> <li>5 to 7.5 mg/kg IV per day once daily</li> </ul> </td> </tr> <tr> <td class="indent1">Amikacin<sup>§</sup></td> <td> <ul> <li><strong>GA &lt;30 weeks:</strong> <ul> <li>Age ≤14 days: 15 mg/kg IV every 48 hours</li> <li>Age &gt;14 days: 15 mg/kg IV every 24 hours</li> </ul> </li> <li><strong>GA 30 to 34 weeks:</strong> <ul> <li>Age ≤10 days: 15 mg/kg IV every 36 hours</li> <li>Age &gt;10 days: 15 mg/kg IV every 24 hours</li> </ul> </li> <li><strong>GA ≥35 weeks:</strong> <ul> <li>Age ≤7 days: 15 mg/kg IV every 24 hours</li> <li>Age &gt;7 days: 18 mg/kg IV every 24 hours</li> </ul> </li> </ul> </td> <td> <ul> <li>15 to 22.5 mg/kg IV per day in 2 or 3 doses or once daily</li> </ul> </td> </tr> <tr> <td class="indent1">Cefotaxime<sup>¥</sup> (if available)</td> <td> <ul> <li> <p>Age &lt;7 days: 50 mg/kg IV every 12 hours</p> </li> <li> <p>Age ≥7 days: 50 mg/kg IV every 8 hours</p> </li> </ul> </td> <td> <ul> <li>150 to 180 mg/kg IV per day in 3 doses</li> <li>200 to 225 mg/kg IV per day in 4 doses for meningitis</li> </ul> </td> </tr> <tr> <td class="indent1">Ceftazidime<sup>¥</sup> (if cefotaxime not available)</td> <td> <ul> <li>Age &lt;7 days: 50 mg/kg IV every 12 hours</li> <li>Age ≥7 days: 50 mg/kg IV every 8 hours</li> </ul> </td> <td> <ul> <li>90 to 150 mg/kg IV per day in 3 doses</li> <li>200 to 300 mg/kg IV per day in 3 doses for suspected <em>Pseudomonas</em> (severe infection)</li> </ul> </td> </tr> <tr> <td class="indent1">Ceftriaxone<sup>¥</sup><sup>‡</sup> (if cefotaxime not available)</td> <td> <ul> <li>50 mg/kg IV every 24 hours</li> </ul> </td> <td> <ul> <li>50 to 75 mg/kg IV per day</li> <li>100 mg/kg IV per day in 1 or 2 doses for meningitis</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Gram stain not available or no organisms seen</td> </tr> <tr> <td class="indent1" colspan="3"><strong>CA-MRSA not a concern</strong></td> </tr> <tr> <td class="indent2">Nafcillin or oxacillin, plus one of the following: <ul class="decimal_heading"> <li>Gentamicin<sup>§</sup></li> <li>Amikacin<sup>§</sup></li> <li>Cefotaxime<sup>¥</sup></li> <li>Ceftazidime<sup>¥</sup></li> <li>Ceftriaxone<sup>¥</sup></li> </ul> </td> <td colspan="2"> <ul> <li>Dosing regimens provided above</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong>CA-MRSA a concern</strong></td> </tr> <tr> <td class="indent2">Clindamycin<sup>¶</sup> or vancomycin, plus one of the following: <ul class="decimal_heading"> <li>Gentamicin<sup>§</sup></li> <li>Amikacin<sup>§</sup></li> <li>Cefotaxime<sup>¥</sup></li> <li>Ceftazidime<sup>¥</sup></li> <li>Ceftriaxone<sup>¥</sup></li> </ul> </td> <td colspan="2"> <ul> <li>Dosing regimens provided above</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to UpToDate content on mastitis and breast abscess in infants for additional information. The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments. Unless otherwise specified, "age" refers to postnatal age.</div><div class="graphic_footnotes">CA-MRSA: community-acquired methicillin-resistant <em>Staphylococcus aureus</em>;
GA: gestational age;
IV: intravenously;
PMA: postmenstrual age;
PNA: postnatal age;
AUC: area under the curve.<br/>
* Severe complications include extensive cellulitis, necrotizing fasciitis, osteomyelitis, and shock. Refer to UpToDate content on mastitis and shock in infants.<br/>
¶ Clindamycin should not be used if central nervous system infection is a concern. Monitor carefully when used if more than 15% of local community-associated <em>S. aureus</em> isolates are resistant to clindamycin.<br/>
Δ Serum creatinine concentration will take approximately 5 to 7 days after birth to reasonably reflect neonatal renal function. Cautious use of creatinine-based dosing strategy with frequent assessment of renal function and vancomycin serum concentrations are recommended in neonates ≤7 days old<sup>[2]</sup>. A vancomycin dosing method based upon PMA and PNA is provided as an alternative to the serum creatinine-based method listed above and may be useful in some clinical situations<sup>[3]</sup>. The regimen was designed with a target trough concentration of 10 to 20 mg/L.
<ul>
<li>PMA ≤29 weeks
    <ul>
<li>PNA ≤21 days: 15 mg/kg IV every 18 hours</li>
<li>PNA &gt;21 days: 15 mg/kg IV every 12 hours</li>
</ul>
</li>
<li>PMA 30 to &lt;37 weeks
    <ul>
<li>PNA ≤14 days: 15 mg/kg IV every 12 hours</li>
<li>PNA &gt;14 days: 15 mg/kg IV every 8 hours</li>
</ul>
</li>
<li>PMA 37 to &lt;45 weeks
    <ul>
<li>PNA ≤7 days: 15 mg/kg IV every 12 hours</li>
<li>PNA &gt;7 days: 15 mg/kg IV every 8 hours</li>
</ul>
</li>
</ul>
<span class="lozenge">◊</span> The approach to vancomycin dosing is generally determined at the institutional level. Refer to UpToDate content on invasive staphylococcal infections in children for details of trough-guided and AUC-guided vancomycin dosing for infants ≥28 days of age.<br/>
§ Initial aminoglycoside dosing is provided. The optimal, individualized dose of amikacin and gentamicin should be based on determination of serum concentrations. Doses may differ from those recommended by the package insert.<br/>
¥ Cefotaxime (if available), ceftazidime, or ceftriaxone is recommended if cerebrospinal fluid is abnormal.<br/>
‡ Intravenous ceftriaxone should be avoided in infants who are also receiving or are expected to receive intravenous calcium in any form, including parenteral nutrition.</div><div class="graphic_reference">References:
<ol>
<li>Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol, 2001; 41:927.</li>
<li>Nelson's Pediatric Antimicrobial Therapy, 27<sup>rd</sup> ed, Bradley JS, Nelson JD, Barnett ED, et al (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.100.</li>
<li>Radu L, Bengry T, Akierman A, et al. Evoluation of empiric vancomycin dosing in a neonatal population. J Perinatol 2018; 38:1702.</li>
</ol>
Data adapted from: American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Ithasca, IL 2021. p.876.</div><div id="graphicVersion">Graphic 111097 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
